Quizartinib for FLT3-ITD (+) Acute Myeloid Leukemia Maintenance
This study is looking at two different doses of quizartinib to help prevent acute myeloid leukemia (AML) from coming back. AML is a type of blood cancer. This trial is for people with a specific type of AML called FLT3-ITD (+), who are in their first complete remission (meaning the cancer is not currently detectable) and have not had a stem cell transplant. Participants will receive either a higher or lower daily dose of quizartinib by mouth. The main goal is to track any serious side effects from the treatment. This study is also looking at how quizartinib might affect your heart rate. About 130 adults aged 18 and older are expected to join.
- Study design
- This is an interventional study comparing two doses of quizartinib in approximately 130 participants. It has two arms, meaning participants will be assigned to one of two treatment groups.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Serious side effects will be monitored from the first dose until 30 days after the last dose, for up to 87 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
At a glance
Conditions
Where it's being run
58 sites across 9 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Serious Treatment Emergent Adverse Events (TEAEs)From date of first dose to 30 days after last dose, up to 87 months
TEAEs are defined as AEs with start or worsening date during the on-treatment period (from the first dose date of trial treatment to 30 days after the last dose date of trial treatment).